张素平 教授
药理学
基础医学院
s9zhang@szu.edu.cn
深圳市南山区西丽学苑大道1066号
1.肿瘤细胞的新靶点的鉴定及其作用机制研究 2.靶向免疫治疗新药研发 3.CAR-T细胞治疗新技术开发
2007年获清华大学博士学位，随后加入加州大学圣地亚哥分校从事博士后科学研究，2012年留校任教。2015年被深圳大学聘为副教授，荔园优青，深圳市海外高层次人才；2023年晋升为教授，博士生导师。
张博士长期致力于肿瘤生物学及免疫靶向治疗新药的研究，利用细胞生物学、生物化学、分子生物学、免疫学、生物信息学等多学科分析方法,研究肿瘤发生、发展、转移及复发的机制及寻找新的治疗靶标，据此开发靶向消除肿瘤细胞或改变其微环境的免疫治疗新药有望治愈癌症。到目前为止，张博士主要开发的进入临床试验阶段的用于免疫治疗的一类新药有两个;发表高水平学术论文27篇，其中第一作者及通讯作者论文16篇(含3篇PNAS)，引用次数超过2000。拥有国内外发明专利9项，其中一项已经商业化;承担国家重点研发计划、国家自然科学基金面上项目、深圳市海外创新孔雀团队等项目共11项。为0ncogene,Cell Death& Disease和 Acta pharmaceutica Sinica B等SCI杂志评审专家。 2011年获得第53届美国血液学年会成就奖。
项目编号： | Title | Granting agency | Amount of total award | Time period of contract/grant | Role |
KQTD20140630100658078 | 针对肿瘤干细胞免疫疗法的研究和开发 | 深圳市科创委 | 1500万人民币 | 04/01/2015-03/31/2020 | 第二核心成员 |
GJHS20170313110507325 | 以生物组学特征与多功能影像为基础的多线束精准放疗方案研究 | 国家卫生和计划生育委员会 | 1200万人民币 | 07/01/2016-06/30/2019 | 国家重点专项子课题的骨干成员 |
81672912 | ROR1在乳腺癌肿瘤干细胞中的作用研究 | 国家基金委面上项目 | 64万人民币 | 01/01/2017-12/30/2020 | 主持 |
RC00155 | 新引进高端人才科研启动项目 | 深圳市科创委 | 270万人民币 | 01/01/2018-12/30/2020 | 主持 |
JCYJ20170818143630465 | 针对乳腺癌肿瘤干细胞的新靶点ROR2的研究及抗体的研发 | 深圳市基础研究（自由探索） | 50万人民币 | 01/01/2018-09/30/2020 | 主持 |
JCYJ20180507182203049 | 针对络氨酸激酶孤儿受体的恶性肿瘤靶向治疗研究 | 深圳市基础研究（学科布局） | 200万人民币 | 04/01/2019-9/31/2022 | 主持 |
81972753 | ROR2在乳腺癌转移和复发中的作用研究
| 国家基金委面上项目 | 55万人民币 | 01/01/2020-12/30/2023 | 主持 |
2020KZDZX1176
| 广东省普通高校新冠肺炎疫情防控专项研究项目（广东省教育厅） | 10万人民币 | 04/01/2020 -03/31/2022 | 主持 | |
ZDSYS20200811143757022 | 深圳市恶性血液病精准诊疗重点实验室 | 深圳市科创委 | 500万人民币 | 04/01/2021-03/31/2023 | 学科带头人 |
32170712 | 酪氨酸激酶孤儿受体对经典Wnt信号通路的调控作用研究 | 国家基金委面上项目 | 58万人民币 | 01/01/2022-12/30/2025 | 主持 |
B2302022 | 消化道肿瘤的靶向免疫治疗研究 | 深圳市医学研究专项项目-前沿探索型（一般项目） | 300万人民币 | 01/01/2024-2026/12/31 | 主持 |
代表性论文：
[1] Su H, Wang Y, Khan S, Huang Y, Yi Z, Zhu N, Li Z, Leng F, Chen Y, Yang L, Matsutani T, Lin Z, Zhang S*, Immunotherapy shapes B-cell receptor repertoire to induce anti-tumor antibodies production in colon and lung cancer, Genome Instability & Disease, 2024, 5:183-196
[2] Su H, Zhang J, Yi Z, Khan S, Peng M, Ye L, Bao A, Zhang H, Suo G, Li Q, Zheng H, Wu D, Kipps TJ, Wang L, Lin Z, Zhang S*, A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif, hLife, 2024,2:126–140
[3] Zeng C, Zou T, Qu J, Chen X, Zhang S*, Lin Z*, Cyclovirobuxine D Induced-Mitophagy through the p65/BNIP3/LC3 Axis Potentiates Its Apoptosis-Inducing Effects in Lung Cancer Cells, International Journal of Molecular Sciences (IF:6.208), 2021, 22:5820
[4]Zhou L, Zhang Y, Wang Y, Zhang M, Sun W, Dai T, Wang A, Wu X, Zhang S, Wang S, Zhou F*, A dual role of type I interferons (IFN-Is) in antitumor immunity, Advanced Biosystems, 2020. 1900237: 1-14
[5]Wang S, Zhou L, Ling L, Meng X, Chu F, Zhang S, Zhou F*, The crosstalk Between Hippo-YAP Pathway and Innate Immunity, Frontiers in Immunology (IF:5.085), 2020, 11:1-14,
[6] Zhou X, Xie F, Wang L, Zhang L, Zhang S, Fang M, Zhou F*, The function and clinical application of extracellular vesicles in innate immune regulation, Cellular&Molecular Immunology (IF:8.484，一区), 2020, 17:323-334
[7] Zhang J, Lin X, Wu L, Huang J, Jiang W, Kipps TJ, Zhang S*, Aurora B induces epithelial–mesenchymal transition by stabilizing Snail1 to promote basal-like breast cancer metastasis, Oncogene (IF: 9.867，一区), 2020, 39:2550-2567
[8] Hasan K, Widhopf II G, Zhang S, Lam S, Shen Z, Briggs S, Parker B, Kipps TJ, Wnt5a Induces ROR1 To Recruit Cortactin To Promote Breast Cancer Migration And Metastasis, npj Breast Cancer(IF:6.000), 2019, 5:35
[9] Chen Y, Chen L, Yu J, Ghia E, Choi M, Zhang L , Zhang S, Sanchez-Lopez E, Widhopf II G, Messer K, Rassenti L, Jamieson C and Kipps TJ, Cirmtuzumab Blocks Wnt5a/ROR1-Stimulation Of NF-κB To Repress Autocrine STAT3- Activation in Chronic Lymphocytic Leukemia, Blood (IF:16.562, 一区), 2019, 134:1084-1094
[10] Zhang S#, Zhang H, Ghia E M, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, Widhopf G F, Yu J, Schwab R, Messer K, Jiang W, Parker B A, Carson D, Kipps TJ, Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody, Proceedings of the National Academy of Sciences of the United States of America (PNAS, IF: 9.681，一区), 2019,116(4):1370-1377
[11] Zhou Y, Kipps TJ, Zhang S*, Wnt5a signaling in normal and cancer stem cells, Stem Cell International (IF: 3.687), 2017, 2017:1-6 /2017.04.12
[12] Yu J, Widhopf G, Chen L, Cui B, Shen Z, Wu R, Zhang L, Zhang S, Briggs SP, Kipps TJ, Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation， Journal of Clinical Investigation (IF:13.215，一区) , 2015,126(2):585-598
[13] Zhang S#, Cui B, Lai H, Liu G, Ghia E M, Widhopf G F, Zhang Z, Wu C C, Chen L, Wu R, Schwab R, Carson D, Kipps TJ, Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy, Proceedings of the National Academy of Sciences of the United States of America(PNAS, IF: 9.681，一区), 2014,111:17266-17271
[14] Cui B, Chen L, Zhang S, Mraz M, Fecteau JF, Yu J, Ghia E, Zhang L, Lei B, Rassenti L, Messer K, Calin GA, Croce CM, Kipps TJ, MicroRNA-155 Influences B-cell Receptor Signaling And Associates With Aggressive Disease In Chronic Lymphocytic Leukemia, 2014, Blood (IF：13.164，一区), 124(4):546-54
[15] Zhang S#, Kipps TJ. The Pathogenesis of Chronic Lymphocytic Leukemia, Annual Review of Pathology, Mechanisms of Disease (IF: 23.758，一区), 2014, 9:103-118
[16] Yan XH, Pan J, Xiong WW, Cheng MZ, Sun YY, Zhang S, Chen YG, Yin Yang 1 (YY1) synergizes with Smad7 to inhibit TGF-β signaling in the nucleus, Science China life science (IF:1.354), 2014, 57:128-134
[17] Cui B#, Zhang S#, Chen L, Yu J, Widhopf G, Fecteau J-F, Rassenti L, Kipps TJ. Targeting ROR1 Inhibits Epithelial-Mesenchymal Transition and Metastasis, (*contributed equally), Cancer Research (IF: 9.284，一区), 2013, 73:3649-3660
[18] Zhang S#, Wu C, Fecteau J-F, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao FS, Weigand S, Kipps TJ, Targeting Chronic Lymphocytic Leukemia Cells with a Humanized Monoclonal Antibody Specific for CD44, Proceedings of the National Academy of Science(PNAS, IF: 9.681，一区), 2013,110:6127-6132
[19] Fecteau J-F, Messmer D, Zhang S, Cui B, Chen L, Kipps TJ. Impact OfOxygen Concentration On Growth of Mesenchymal Stromal Cells From The Marrow Of Patients With Chronic Lymphocytic Leukemia. Blood(IF: 13.164，一区), 2012, 121:971-974
[20] Zhang S#, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, Wu R, Kipps TJ: The Onco-Embryonic Antigen ROR1 Is Expressed By A Variety Of Human Cancers, American Journal of Pathology(IF: 5.575), 2012, 181:1903-10
[21] Zhang S#, Chen L, Cui B, Chuang HY, Yu J, Wang-Rodriguez J, Tang L, Chen G, Basak GW, Kipps TJ: ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell Growth, PLoS One (IF: 4.092)2012, 7:e31127
[22] Shi X, Chen F, Yu J, Xu Y, Zhang S, Chen YG, Fang X. Study of interaction between Smad7 and DNA by single-molecule force spectroscopy, Biochemical Biophysical Research Communications (IF: 2.548), 2008, 377:1284-7
[23] Zhang S#, Fei T., Zhang L., Zhang R., Chen F., Ning Y., Feng X., Meng A., Chen YG., Smad7 antagonizes TGF-β signaling in the nucleus by interfering with functional Smad-DNA complex formation, Molecular Cell Biology (IF: 6.598), 2007, 27:4488-4499
[24] Liu W, Rui H, Wang J, Lin S, He Y, Chen M, Li Q, Ye Z, Zhang S, Chan S, Chen YG, Han J, Lin S. Axin is a scaffold protein in TGF-beta signaling that promotes degradation of Smad7 by Arkadia. TheEMBO Journal (IF: 10.086，一区), 2006, 25:1646-1658
[25] Zhang S#, Zhou W. , Ding Y. , He X. , Zhang H. , An J. , Gao F. , Heckmann K. , Liang A. , Rao Z. , Preliminary X-ray crystallographic analysis of ciliate euplotes octocarinatus release factor eRF1a, Protein and Peptide Letters, 2002, 9(1):81-85
[26] Zhang S#, He X, Yuan J, Liang A, Expression, Purification and Identification of eRF1a of Euplotes octocarinatus, Chinese Journal of Biochemistry and Molecular Biol, 2002,18(01): 23-26
[27] Zhang S#, Liang A, The Advances on the Release Factors (Class 1) in Translation Termination, Progress In Biochemistry and Biophysics, 2001, 28(5): 619-622
授权专利：
1) 张素平，汤姆·科佩斯，吴柳风，检测多种恶性肿瘤细胞的抗体及其应用，日期：2019-01-08，申请号/专利号： ZL201910015053.3，授权日期：2021-08-10，并申请PCT国际专利。
2) 张素平，汤姆·科佩斯，吴柳风，张建超，治疗恶性肿瘤的抗体及其应用，申请日期：2019-01-08，申请号/专利号：ZL201910015048.2，授权日期：2021-08-24，并申请PCT国际专利。
3) Kipps TJ, Fukuda T, Endo T, Zhang S, Chen L, Broom EH, Methods and compounds for lymphoma cell detection and isolation, 2010, US 2010/0062005 A1, 已授权并商业化
申请发明专利：
1) 张素平，苏杭，移振飞，治疗和检测新型冠状病毒肺炎的抗体及其应用，日期：2021年12月17日，申请号：202111553043.9
2) Zhang S, Kipps TJ, Wu L, Antibodies for detecting various tumor cells and uses thereof, Date: 2021-07-08, Appl. No.: 17/369,988
3) Zhang S, Kipps TJ, Wu L, Zhang J, Antibodies for treating malignant tumors and uses thereof, Date: 2021-07-08, Appl. No.: 17/369,989
4) 张素平，张悦，王亦萌，李正浩，何超，一种靶向ROR2的嵌合抗原受体、表达基因、表达载体、T细胞及其应用，日期：2020-09-01申请号：202010914145.8
5) Kipps TJ, Zhang S, Ghia E, Combination treatment of chemoresistant cancers, International filling date: 2019-11-03 , International publication number: WO 2019/173843 A1
6) Kipps TJ, Zhang S, Wu C, CD44 monoclonal antibody for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies, 2012, UCSD Docket No: SD2012-116-1
用户登录
还没有账号？
立即注册